{"title":"弥合差距:PSMA放射治疗亚洲男性前列腺癌。","authors":"Minseok Suh, Joo Hyun O","doi":"10.1007/s13139-025-00946-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is transforming the treatment landscape for prostate cancer. However, clinical data and outcomes for Asian patients remain limited and they are underrepresented in pivotal clinical trials. Although emerging retrospective series from Asia demonstrate comparable efficacy and safety profiles to Western cohorts, several points warrant attention. Asian men frequently present with aggressive, advanced-stage disease and distinct genomic profiles, characterized by lower rates of ERG fusions and TP53/PTEN mutations, and higher frequencies of FOXA1 and SPOP alterations. These genomic differences could influence PSMA expression and responsiveness to therapy. Additionally, Asian populations exhibit higher susceptibility to myelosuppression, necessitating careful patient selection and dose management. The development of region-specific radiopharmaceuticals and clinical trials, alongside systematic real-world data collection, will be essential for optimizing PSMA-targeted RLT in Asian contexts. Incorporating PSMA-based therapies earlier in disease management strategies also presents promising avenues for improving outcomes. Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 5","pages":"342-350"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446156/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.\",\"authors\":\"Minseok Suh, Joo Hyun O\",\"doi\":\"10.1007/s13139-025-00946-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is transforming the treatment landscape for prostate cancer. However, clinical data and outcomes for Asian patients remain limited and they are underrepresented in pivotal clinical trials. Although emerging retrospective series from Asia demonstrate comparable efficacy and safety profiles to Western cohorts, several points warrant attention. Asian men frequently present with aggressive, advanced-stage disease and distinct genomic profiles, characterized by lower rates of ERG fusions and TP53/PTEN mutations, and higher frequencies of FOXA1 and SPOP alterations. These genomic differences could influence PSMA expression and responsiveness to therapy. Additionally, Asian populations exhibit higher susceptibility to myelosuppression, necessitating careful patient selection and dose management. The development of region-specific radiopharmaceuticals and clinical trials, alongside systematic real-world data collection, will be essential for optimizing PSMA-targeted RLT in Asian contexts. Incorporating PSMA-based therapies earlier in disease management strategies also presents promising avenues for improving outcomes. Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>\",\"PeriodicalId\":19384,\"journal\":{\"name\":\"Nuclear Medicine and Molecular Imaging\",\"volume\":\"59 5\",\"pages\":\"342-350\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446156/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13139-025-00946-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-025-00946-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.
Abstract: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is transforming the treatment landscape for prostate cancer. However, clinical data and outcomes for Asian patients remain limited and they are underrepresented in pivotal clinical trials. Although emerging retrospective series from Asia demonstrate comparable efficacy and safety profiles to Western cohorts, several points warrant attention. Asian men frequently present with aggressive, advanced-stage disease and distinct genomic profiles, characterized by lower rates of ERG fusions and TP53/PTEN mutations, and higher frequencies of FOXA1 and SPOP alterations. These genomic differences could influence PSMA expression and responsiveness to therapy. Additionally, Asian populations exhibit higher susceptibility to myelosuppression, necessitating careful patient selection and dose management. The development of region-specific radiopharmaceuticals and clinical trials, alongside systematic real-world data collection, will be essential for optimizing PSMA-targeted RLT in Asian contexts. Incorporating PSMA-based therapies earlier in disease management strategies also presents promising avenues for improving outcomes. Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients.
期刊介绍:
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.